Skip to main content
Premium Trial:

Request an Annual Quote

Epidauros and InPheno to Co-Market Their PGx Services

NEW YORK (GenomeWeb News) — Epidauros and InPheno earlier this week said they plan to co-market their pharmacogenomic and phenotypic services to drug developers as a single service.
“We are trying to bring both genotype and phenotype analysis together because genetic analysis alone is not sufficient to predict statistical variance in clinical outcomes,” Hans Peter Arnold, director of business development and marketing at Epidauros, told GenomeWeb News this week.
The partnership could begin with marketing HIV services. InPheno already has an HIV analysis service, and Arnold said Epidauros expects to expand in that direction.
Epidauros CEO Michael Lutz said that adding InPheno’s capabilities in virology, oncology, and other diseases counts as an “important expansion” of the company’s clinical genotyping services.
Financial terms of the agreement were not released.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.